Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
InMode (DE:154)
FRANKFURT:154
InMode (154) Stock Price & Analysis
3 Followers
154 Stock Chart & Stats
Day’s Range€16.1 - €16.1
52-Week Range― - ―
Previous Close€15.93
Volume0.00
Average Volume (3M)N/A
Market Cap
$1.36B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
Jul 25, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€27.94Price Target Upside73.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
InMode News
PremiumCompany Announcements
InMode Announces Q1 Results and Share Buyback
Bulls Say, Bears Say
Bulls Say
Financial StrengthINMD ended the quarter with a strong cash position and announced a share repurchase authorization.
Growth PotentialManagement has started booking orders for not yet released new product launches and a backlog is building, setting up for a story of accelerating growth.
Market ExpansionManagement believes market penetration is still low, indicating potential for growth.
Bears Say
Financial PerformanceINMD's operating margin was below consensus and decreased significantly year-over-year due to deleveraging.
Market ExpectationsAnalyst maintains a Hold rating given the uncertain economic outlook and potential for M&A which could dilute INMD's margins.
Revenue ForecastMgmt reduced full-year sales expectations by $10 mil to $985 – 995 mil, reflecting a slowdown in volumes and system demand in the U.S.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.00% Mutual Funds
10.15% Other Institutional Investors
89.85% Public Companies and
Individual Investors
154 FAQ
What was InMode’s price range in the past 12 months?
Currently, no data Available
What is InMode’s market cap?
Currently, no data Available
When is InMode’s upcoming earnings report date?
InMode’s upcoming earnings report date is Jul 25, 2024 which is in 80 days.
How were InMode’s earnings last quarter?
InMode released its earnings results on May 02, 2024. The company reported €0.299 earnings per share for the quarter, missing the consensus estimate of €0.414 by -€0.116.
Is InMode overvalued?
According to Wall Street analysts InMode’s price is currently Undervalued.
Does InMode pay dividends?
InMode does not currently pay dividends.
What is InMode’s EPS estimate?
InMode’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InMode have?
Currently, no data Available
What happened to InMode’s price movement after its last earnings report?
InMode reported an EPS of €0.299 in its last earnings report, missing expectations of €0.414. Following the earnings report the stock price went up 1.099%.
Which hedge fund is a major shareholder of InMode?
Among the largest hedge funds holding InMode’s share is North Growth Management Ltd.. It holds InMode’s shares valued at 12M.
---
InMode Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€27.94 (73.54% Upside)
€27.94 (73.54% Upside)
Blogger Sentiment
Bullish
DE:154 Sentiment 86%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.68%
12-Months-Change
Fundamentals
Return on Equity
25.54%
Trailing 12-Months
Asset Growth
33.17%
Trailing 12-Months
Company Description
InMode
InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. It also designs, develops, manufactures and markets non-invasive medical aesthetic products that target a array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture and superficial benign vascular and pigmented lesions. The company was founded by Moshe Mizrahy and Michael Kreindel on January 2, 2008 and is headquartered in Yokneam, Israel.
---
154 Company Deck
---
154 Earnings Call
Q1 2024
0:00 / 0:00
---
154 Stock 12 Months Forecast
Average Price Target
€27.94
▲(73.54% Upside)
Technical Analysis
Best Analysts Covering 154
1 Year
1 Year Success Rate
9/25 ratings generated profit
1 Year Average Return
+10.43%
reiterated a buy rating 27 days ago
Copying Jeff Johnson's trades and holding each position for 1 Year would result in 36.00% of your transactions generating a profit, with an average return of +10.43% per trade.
---